risedronate

Risedronate is a nitrogen-containing (third-generation) bisphosphonate that binds to hydroxyapatite in bone and is internalized by osteoclasts during resorption. Within osteoclasts, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, preventing protein prenylation of small GTPases essential for osteoclast function, leading to osteoclast apoptosis. Its pyridinyl side chain provides high potency, and weekly or monthly dosing regimens are available due to prolonged skeletal binding.

Adult

with dose and duration of therapy. g Bone-protection treatment should be started at the onset of therapy in patients who are at a high risk of fracture. If glucocorticoid therapy is stopped, the need to continue bone-protection treatment should be reviewed. However, bone-protection treatment should be continued with longterm glucocorticoid therapy.…

• abnormalities that delay esophageal emptying
• Gastroesophageal reflux
• Peptic ulcer
• Renal impairment (general BPN contraindications)